
Blau Farmaceutica SA
BOVESPA:BLAU3

Intrinsic Value
The intrinsic value of one
BLAU3
stock under the Base Case scenario is
25.53
BRL.
Compared to the current market price of 14.27 BRL,
Blau Farmaceutica SA
is
Undervalued by 44%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Blau Farmaceutica SA
Fundamental Analysis


Revenue & Expenses Breakdown
Blau Farmaceutica SA
Balance Sheet Decomposition
Blau Farmaceutica SA
Current Assets | 1.6B |
Cash & Short-Term Investments | 442.1m |
Receivables | 514.8m |
Other Current Assets | 690.4m |
Non-Current Assets | 1.8B |
Long-Term Investments | 265.2m |
PP&E | 882m |
Intangibles | 501.1m |
Other Non-Current Assets | 136.5m |
Free Cash Flow Analysis
Blau Farmaceutica SA
BRL | |
Free Cash Flow | BRL |
Earnings Waterfall
Blau Farmaceutica SA
Revenue
|
1.8B
BRL
|
Cost of Revenue
|
-1.1B
BRL
|
Gross Profit
|
688.6m
BRL
|
Operating Expenses
|
-298.1m
BRL
|
Operating Income
|
390.5m
BRL
|
Other Expenses
|
-122.4m
BRL
|
Net Income
|
268.1m
BRL
|
BLAU3 Profitability Score
Profitability Due Diligence
Blau Farmaceutica SA's profitability score is 56/100. The higher the profitability score, the more profitable the company is.

Score
Blau Farmaceutica SA's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
BLAU3 Solvency Score
Solvency Due Diligence
Blau Farmaceutica SA's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Score
Blau Farmaceutica SA's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BLAU3 Price Targets Summary
Blau Farmaceutica SA
According to Wall Street analysts, the average 1-year price target for
BLAU3
is 18.3 BRL
with a low forecast of 15.15 BRL and a high forecast of 23.63 BRL.
Dividends
Current shareholder yield for BLAU3 is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
BLAU3
stock under the Base Case scenario is
25.53
BRL.
Compared to the current market price of 14.27 BRL,
Blau Farmaceutica SA
is
Undervalued by 44%.